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Abstract
This study aims to analyze the inhibitory activities of aqueous root extract compounds of Ruellia tuberosa L. toward alphaglucosidase protein by computational docking analysis. Three major compounds contained in the extracts (i.e., betaine,
daidzein, and hispidulin) were selected as ligands; quercetin and acarbose were used as the reference. Computational
docking analysis was performed using the HEX 8.0.0 program and visualized using the Discovery Studio Visualizer
v19.1.0.18287 (2019 version) on the basis of the scoring functions. The interactions between ligands and alpha-glucosidase
protein showed different binding patterns. The types of bonds involved in the interaction between the enzyme and these
ligands were hydrogen and hydrophobic bonds. Energy generated from docking of betaine, daidzein, hispidulin, quercetin,
and acarbose to alpha-glucosidase protein were −167.6, −249.5, −251.2, −241.5, and −322.1 cal/mol, respectively. Acarbose had the lowest energy, indicating that it has the strongest interaction with alpha-glucosidase, followed by hispidulin,
daidzein, quercetin, and betaine. Amino acid residues that interacted with the ligands were His717, Met363, Arg608,
Pro361, Phe362, Leu865, Glu869, Arg594, andAsp356. The current research shows that R. tuberosa L. aqueous root extracts have the potential to be used as an inhibitor for the alpha-glucosidase protein and as an antidiabetic agent. Nonetheless, further studies are needed to support this modeling study.
Keywords: alpha-glucosidase; betaine; daidzein; hispidulin; in silico; R. tuberosa L.

major factor for the development of cardiovascular
diseases and cancer [4].

Introduction
Diabetes mellitus, a carbohydrate metabolic disorder
characterized by high blood glucose levels, has become a major public health concern. In 2010, the International Diabetes Federation reported an onset rate
of approximately 6.4% in adults and a total of 285 million cases of diabetes globally. This number is projected to increase to 439 million cases in 2030 [1]. There
are two types of diabetes mellitus. Insulin-dependent
diabetes mellitus or Type 1 DM is caused by the autoimmune destruction of insulin-producing pancreatic β
cells. The hypoinsulinemic state when hyperglycemia
ensues, which is a dangerous physiological state, must
be countered by regular insulin injections for survival.
In non-insulin-dependent diabetes mellitus or Type 2
DM, insulin-sensitive cells are resistant to the actions
of insulin [2], [3]. As a result, the metabolic reactions
that are stimulated in β cells to produce extra insulin
are inadequate to maintain blood glucose homeostasis,
and the elevated concentration of insulin secreted is a

Type 2 DM is prevalent with more than 90% of reported
cases worldwide [3]. The pathogenesis of Type 2 DM
remains unknown because several malfunctioning
mechanisms occur concurrently that can contribute to
the progress of the disease. Along with genetic factors
in individuals that affect the progress of this disease,
numerous aspects, including obesity, lack of physical
exercise, and poor nutrition practices, can contribute to
its development [4]. Type 2 DM can cause other
chronic diseases, including cardiovascular diseases,
nephropathy, retinopathy, and neuropathy [4], which
will decrease life expectancy and increase disability.
Consequently, the safe and effective management of Type
2 DM is a top priority for researchers and clinicians.
The established drugs for Type 2 DM treatment include dipeptidyl peptidase 4 (DPP-4) inhibitors, glucagon-like peptide 1 (GLP-1) receptor agonists, metfor51
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min, sulphonylureas, thiazolidinediones, and alphaglucosidase inhibitors [5]–[9]. Mild to severe adverse
effects have been reported for some of these drugs.
Upper respiratory tract infections have been increasingly reported among users of DPP-4 inhibitors compared with users of other antidiabetic drugs [10]. Animal studies indicated an association of GLP-1 receptor
agonists with pancreatitis, pancreatic cancer, and thyroid cancer [11]. The use of thiazolidinediones or sulphonylureas may increase fracture risk, which can be
attributed to an increased risk of hypoglycemiainduced falls [12]. Metformin has been reported to
have a few side effects, including gastrointestinal
symptoms, nausea, and vomiting [13]. Alphaglucosidase inhibitors are reported to adequately control Type 2 DM. However, marketed drugs have different side effects and are expensive, which lead to
poor patient compliance. Thus, alpha-glucosidase inhibitors need to be effective, safe, and affordable to
ensure patient compliance [14–15].

L. contained mostly flavonoid and phytosterol compounds [24–25]. R. tuberosa L. aqueous root extracts
also showed antidiabetic activity in in vivo studies
[26–28]. LC-MS analysis revealed that betaine, daidzein, and hispidulin were detected in R. tuberosa L.
aqueous root extracts [24]. Therefore, these compounds were selected as ligands and docked to alphaglucosidase protein. Quercetin and acarbose are used
as the positive ligand reference. Quercetin is a flavonoid compound that is found abundantly in vegetables
and fruits and has many pharmacological activities
[29], including antioxidant, anti-inflammatory, and
anticancer activities [30]. Meanwhile, acarbose is one
of the potent alpha-glucosidase inhibitors and has recently been recommended for the treatment of diabetes
[31]. Furthermore, acarbose has received preferred
status over other oral glucose-lowering drugs because
of its proven capability to reduce cardiovascular diseases [31–33].

Methods
Alpha-glucosidase inhibitors are regular antidiabetic
drugs used to monitor carbohydrates converted into
simple sugars and absorbed by the intestines. Drugs
designed to diminish blood glucose levels and sustain
glucose homeostasis derived from nature are attracting
considerable attention. Many studies have been performed to discover substitute remedies from natural
products that can lessen hyperglycemia through the
downregulation of alpha-glucosidase activity [16, 8],
[17–19]. Nevertheless, the exact mechanisms of action
are still unknown.
The in silico molecular docking approach utilizes a
simulation model that predicts molecular interaction,
including The in silico molecular docking approach
utilizes a simulation model that predicts molecular
interaction, including protein–protein or ligand–
protein interactions. Previous studies have investigated
the interactions between flavonoid compounds and
alpha-amylase protein, which is an important enzyme
for the targeted treatment of diabetes [20–22]. Another
study has also conducted in silico molecular docking
of many natural compounds, such as curcumin, quercetin, berberine, catechin, and rutin, to both alphaamylase and alpha-glucosidase enzymes [23]. Our previous study has also performed in silico molecular
docking of Ruellia tuberosa L. aqueous root extracts to
the alpha-amylase protein [24]. In summary, the
aforementioned studies concluded that natural compounds showed inhibitory activities toward alphaamylase and alpha-glucosidase proteins, thus having
antidiabetic capacity.
The current study investigates the biological activity of
the ligands contained in R. tuberosa L. aqueous root
extracts using the in silico molecular docking approach. Our previous studies showed that R. tuberosa
Makara J. Sci.

Ligand and Protein Preparation for Molecular
Docking Analysis. The 3D structures of aqueous root
extract compounds of R. tuberosa L., i.e., betaine (CID
247), daidzein (CID 5281708), and hispidulin (CID
5281628), were downloaded from the PubChem NCBI
database. Acarbose (CID 41774) and quercetin (CID
5280343) were used as the positive ligand reference.
The pharmacological activities of metabolite compounds
from R. tuberosa L., in particular as an inhibitor for
alpha-glucosidase, were calculated using the Prediction
of Activity Spectra for Substance (PASS) analysis
online software (http://www.way2drug.com/passonline).
To minimize the energies of the compounds and convert
the SDF format into PDB format, the PyRx Virtual
Screening Tool software was operated. The human
alpha-glucosidase protein was obtained from the RCSB
Protein Data Bank, with PDB ID: 5kzx
(http://www.rcsb.or g/pdb). The Discovery Studio
Visualizer v19.1.0.18287 program was used to remove
other ligands or water that linked to the enzyme.
Simulations of Molecular Docking. Ligands (i.e.,
betaine, daidzein, hispidulin, acarbose, and quercetin)
were docked to human alpha-glucosidase protein. The
interaction and binding energy formed between betaine,
daidzein, hispidulin, and quercetin to alpha-glucosidase
enzyme were calculated using the blind docking HEX
8.0.0 software with Shape + Electro + DARS and root–
mean–square deviation (RMSD) value ≤ 2 Å as docking
parameter. A total of 10 runs were performed for each
molecular docking. The visualization of the docking
results was analyzed using the Discovery Studio
Visualizer v19.1.0.18287 program. The molecular
structures of the ligands are shown in Figure 1.
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Figure 1. Molecular Structures of (a) Betaine (CID 247), (b) Daidzein (CID 5281708), (c) Hispidulin (CID 5281628), (d)
Quercetin (CID 5280343), and (e) Acarbose (CID 41774). The Molecular Structures were Adapted from the PubChem NCBI Database

Results and Discussion
The validation of the docking results was conducted
using the RMSD value. All docking results have an
RMSD value ≤ 2.0 Å. The docking accuracy is based on
the RMSD value of the locations of all heavy atoms of
the ligand in the docked pose in the crystal structure. An
RMSD value < 2.0 Å is acceptable [34]. The molecular
docking of betaine, daidzein, hispidulin, quercetin, and
acarbose to human alpha-glucosidase protein has been
conducted to examine the interaction between these
ligands and the protein. The ligand–protein interactions
are denoted by the chemical bonds formed and the binding sites of amino acid residues (Table 1). The molecular docking results are presented in Figures 2 to 6.
The three amino acid residues in human alphaglucosidase that interacted directly with betaine (Figure
2) were His717, Val867, and Leu868. These interactions
were facilitated by carbon and conventional hydrogen
bond formation. The amino acid residues that interacted
with betaine through Van der Waals forces were
Met363, Arg594, Ser864, Leu865, Glu866, and Glu869.
The binding energy of the betaine–human alphaglucosidase complex was −167.6 cal/mol.

Makara J. Sci.

By contrast, daidzein was observed to bind to the different binding positions of human alpha-glucosidase, with
the binding energy of 249.5 cal/mol (Figure 3). The
daidzein–human alpha-glucosidase complex had a higher number of interactions than the betaine–human alphaglucosidase complex (Table 1). On the basis of the molecular docking results shown in Figure 3, Ser265 was
the amino acid residue that bonded to daidzein by establishing a conventional hydrogen bond, whereas Pro266,
Leu269, and Ile276 mediated pi-alkyl through hydrophobic interactions. The amino acid residues that interacted with daidzein through Van der Waals forces were
His263, Leu264, Met268, Ser270, Thr274, Arg275,
Thr277, Gly288, Ala289, and Asn290.
Four hydrogen bonds formed during the interaction between hispidulin and alpha-glucosidase protein (Figure
4). The amino acid residues involved in hydrogen bond
formation were Tyr360, Met363, Ser864, and Glu866.
Two amino acid residues, namely, Arg608 and His717,
formed hydrophobic interactions with hispidulin. Other
residues, including Gly359, Pro361, Phe362, Arg594,
Leu865, Val867, Leu868, and Glu869, interacted with
hispidulin through Van der Waals forces. The binding
energy of the hispidulin–human alpha-glucosidase complex was −251.2 cal/mol.
March 2021  Vol. 25  No. 1
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Table 1. Results of the Interaction between Human Alpha-glucosidase and Betaine, Daidzein, Hispidulin, Quercetin, and
Acarbose by Molecular Docking Analysis
Compounds

Betaine

Daidzein

Hispidulin

Quercetin

Acarbose

Energy
(cal/mol)

–167.6

–249.5

–251.2

–241.5

–332.1

Interaction*

Distance
Chemistry Bond
(Å)

Types

A:VAL867:HN - :LIG1:O

2.199

Hydrogen Bond

Conventional Hydrogen Bond

A:LEU868:HN - :LIG1:O
:LIG1:H - A:HIS717:NE2

2.830
2.594

Hydrogen Bond
Hydrogen Bond

Conventional Hydrogen Bond
Carbon Hydrogen Bond

:LIG1:H - :LIG1:O

2.432

Hydrogen Bond

Carbon Hydrogen Bond

A:SER265:HG - :LIG1:O

2.128

Hydrogen Bond

Conventional Hydrogen Bond

:LIG1 - A:LEU269
:LIG1 - A:PRO266

5.038
4.400

Hydrophobic
Hydrophobic

Pi-Alkyl
Pi-Alkyl

:LIG1 - A:ILE276

4.453

Hydrophobic

Pi-Alkyl

A:TYR360:HN - :LIG1:O

2.228

Hydrogen Bond

Conventional Hydrogen Bond

A:MET363:HN - :LIG1:O
A:GLU866:HN - :LIG1:O

2.052
2.294

Hydrogen Bond
Hydrogen Bond

Conventional Hydrogen Bond
Conventional Hydrogen Bond

:LIG1:H - :LIG1:O
:LIG1:H - A:SER864:O

2.214
2.933

Hydrogen Bond
Hydrogen Bond

Conventional Hydrogen Bond
Carbon Hydrogen Bond

A:HIS717 - :LIG1
:LIG1 - A:ARG608

3.478
4.399

Hydrophobic
Hydrophobic

Pi-Pi T-shaped
Pi-Alkyl

A:HIS717:HD1 - :LIG1:O

2.509

Hydrogen Bond

Conventional Hydrogen Bond

:LIG1:H - :LIG1:O
:LIG1:H - A:GLU196:O

2.216
2.897

Hydrogen Bond
Hydrogen Bond

Conventional Hydrogen Bond
Conventional Hydrogen Bond

:LIG1:H - A:ARG608:O
A:PRO198:C - :LIG1:O

2.749
3.331

Hydrogen Bond
Hydrogen Bond

Conventional Hydrogen Bond
Carbon Hydrogen Bond

A:GLY359:CA - :LIG1:O
A:ARG608:NH1 - :LIG1

3.451
3.938

Hydrogen Bond
Electrostatic

Carbon Hydrogen Bond
Pi-Cation

A:ARG608:NH2 - :LIG1
:LIG1 - A:ARG608

3.577
4.149

Electrostatic
Hydrophobic

Pi-Cation
Pi-Alkyl

A:VAL357:O - :LIG1:O

2.092

Unfavorable

Unfavorable Bump

A:ARG178:HH21 - :LIG1:O

2.581

Hydrogen Bond

Conventional Hydrogen Bond

:LIG1:H - :LIG1:O
:LIG1:H - A:ASP356:O

2.294
2.944

Hydrogen Bond
Hydrogen Bond

Conventional Hydrogen Bond
Conventional Hydrogen Bond

:LIG1:H - A:LEU355:O
:LIG1:H - A:HIS717:O

2.434
2.811

Hydrogen Bond
Hydrogen Bond

Conventional Hydrogen Bond
Conventional Hydrogen Bond

A:ASP356:CA - :LIG1:O
:LIG1:H - A:ASP356:OD2

3.311
2.445

Hydrogen Bond
Hydrogen Bond

Carbon Hydrogen Bond
Carbon Hydrogen Bond

:LIG1:H - A:ASP356:O
:LIG1:H - A:LEU355:O

2.436
2.940

Hydrogen Bond
Hydrogen Bond

Carbon Hydrogen Bond
Carbon Hydrogen Bond

:LIG1:H - :LIG1:O
:LIG1:H - :LIG1:O

2.420
2.779

Hydrogen Bond
Hydrogen Bond

Carbon Hydrogen Bond
Carbon Hydrogen Bond

:LIG1:H - :LIG1:O
2.618
Hydrogen Bond
Carbon Hydrogen Bond
:LIG1:O - A:TYR360
2.963
Other
Pi-Lone Pair
*The H-donors in betaine–human alpha-glucosidase interactions; H-donors and pi-orbitals in daidzein–human alpha-glucosidase
interactions; H-donors and pi-orbitals in hispidulin–human alpha-glucosidase interactions; H-donors, positive ion, pi-orbitals, and
steric ligand in quercetin–human alpha-glucosidase interactions; and H-donors and pi-orbitals in acarbose–human alpha-glucosidase
interactions are rendered in bold.
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Figure 2. Model of the Interaction between Human Alpha-glucosidase Protein and Betaine: (a) Overview; (b) the 3D Structure of the Betaine–human Alpha-glucosidase Complex; and (c) the 2D Structure of the Betaine–human Alpha
Glucosidase Complex

Figure 3. Model of the Interaction between Human Alpha-glucosidase Protein and Daidzein: (a) Overview; (b) the 3D
Structure of the Daidzein–human Alpha-glucosidase Complex; and (c) the 2D Structure of the Daidzein–human
Alpha Glucosidase Complex

Figure 4. Model of the Interaction between Human Alpha-glucosidase Protein and Hispidulin: (a) Overview; (b) the 3D
Structure of the Hispidulin–human Alpha-glucosidase Complex; and (c) the 2D Structure of the Hispidulin–human
Alpha Glucosidase Complex

By contrast, daidzein was observed to bind to the
different binding positions of human alpha-glucosidase,
with the binding energy of 249.5 cal/mol (Figure 3).
The daidzein–human alpha-glucosidase complex had a
higher number of interactions than the betaine–human
alpha-glucosidase complex (Table 1). On the basis of
the molecular docking results shown in Figure 3, Ser265
was the amino acid residue that bonded to daidzein by
establishing a conventional hydrogen bond, whereas
Pro266, Leu269, and Ile276 mediated pi-alkyl through
hydrophobic interactions. The amino acid residues that
interacted with daidzein through Van der Waals forces
were His263, Leu264, Met268, Ser270, Thr274,
Arg275, Thr277, Gly288, Ala289, and Asn290.
Makara J. Sci.

Four hydrogen bonds formed during the interaction
between hispidulin and alpha-glucosidase protein
(Figure 4). The amino acid residues involved in
hydrogen bond formation were Tyr360, Met363,
Ser864, and Glu866. Two amino acid residues, namely,
Arg608 and His717, formed hydrophobic interactions
with hispidulin. Other residues, including Gly359,
Pro361, Phe362, Arg594, Leu865, Val867, Leu868, and
Glu869, interacted with hispidulin through Van der
Waals forces. The binding energy of the hispidulin–
human alpha-glucosidase complex was −251.2 cal/mol.
The binding energy of the interaction between alphaglucosidase protein and quercetin used as the positive
March 2021  Vol. 25  No. 1
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ligand reference was −241.5 cal/mol. The quercetin–
human alpha-glucosidase complex had a slightly higher
number of interactions than the hispidulin–human
alpha-glucosidase complex (Table 1). On the basis of
the molecular docking results shown in Figure 5,
Glu196, Gly359, Arg608, and His717 were the amino
acid residues that bonded to quercetin by establishing
hydrogen bonds. The only amino acid residue that
interacted with quercetin through pi-cation electrostatic
and pi-alkyl hydrophobic bonds was Arg608. The rest
of the amino acid residues, i.e., Leu195, Thr197,
Asp356, Val358, Tyr360, Pro361, Phe362, and Met363,
interacted with hispidulin through Van der Waals bonds.
An unfavorable interaction was observed between
quercetin and Val357 residue.
Another ligand used as a reference is acarbose. The four
amino acid residues that interacted with acarbose
through hydrogen bonds are Arg178, Leu355, Asp356,
and His717, as shown in Figure 6. The pi-lone pair
interaction was observed in the interaction between
Tyr360 and acarbose. Van der Waals forces were

formed between alpha-glucosidase and acarbose
through the following amino acid residues: Met146,
Met172, Glu174, Thr175, Thr197, Pro198, Arg608, and
Val718. The binding energy of −332.1 cal/mol of the
acarbose–human alpha-glucosidase complex was the
lowest among all of the ligands used, indicating that
acarbose had the strongest binding affinity to alphaglucosidase protein.
The biological potential of the compounds belonging to
particular classes of active compounds as inhibitors for
alpha-glucosidase was predicted using PASS analysis.
PASS analysis estimates the probable biological activity
profiles for the investigated compounds on the basis of
their structural formulas presented in MOL or SD file
format. The average accuracy of prediction estimated in
the leave-one-out cross-validation procedure for the
entire PASS set is approximately 96%. The scores
obtained by PASS analysis for betaine, daidzein,
hispidulin, quercetin, and acarbose as alpha-glucosidase
inhibitors are listed in Table 2. Acarbose and quercetin
as control ligands showed the highest and second

Figure 5. Model of the Interaction between Human Alpha-glucosidase Protein and Quercetin: (a) Overview; (b) the 3D
Structure of the Quercetin–human Alpha-Glucosidase Complex; and (c) the 2D Structure of the Quercetin–
human Alpha-glucosidase Complex

Figure 6. Model of the Interaction between Human Alpha-Glucosidase Protein and Acarbose: (a) overview; (b) the 3D
Structure of the Acarbose–human Alpha-glucosidase Complex; and (c) the 2D Structure of the Acarbose–human
Alpha-glucosidase Complex
Table 2. Results of the Pharmacological Activities of Betaine, Daidzein, Hispidulin, Quercetin, and Acarbose as Alphaglucosidase Inhibitors
Alpha glucosidase inhibitor

Acarbose
Pa
Pi
0.956
0

Quercetin
Pa
Pi
0.36 0.093

Hispidulin
Pa
Pi
0.191 0.005

Daidzein
Pa
Pi
0.244 0.004

Betaine
Pa
Pi
nd
nd

*Pa is potentially active, Pi is potentially inactive. The Pa and Pi values were obtained by PASS analysis,
http://www.way2drug.com/passonline.
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Figure 7. 2D Structure Map of the Alpha-glucosidase Protein. The Vertical Red Lines Indicate the Active Site of Alphaglucosidase, and the Vertical Black Lines Indicate the Catalytic site of the Enzyme. B = betaine, D = daidzein, H =
hispidulin, Q = quercetin, and A = acarbose are the Amino Acid Sites that Bind to the Ligands. The 2D Structure
Map of the Alpha-glucosidase Protein was Derived from Reference [40]
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highest activities as alpha-glucosidase inhibitors,
respectively. Daidzein had a higher score as alphaglucosidase inhibitor than hispidulin. Nonetheless,
betaine was not active as an inhibitor for alphaglucosidase, as the score was undetected.

Nevertheless, the order of activity of the investigated
compounds based on the PASS analysis is acarbose >
quercetin > daidzein > hispidulin > betaine.

Figure 7 shows that some of the ligands used in this
study bonded to the same amino acid residues. For
instance, betaine, hispidulin, quercetin, and acarbose
interacted with His717; betaine, hispidulin, and quercetin
interacted with Met363; and hispidulin, quercetin, and
acarbose interacted with Arg608. Moreover, Pro361 and
Phe362 bonded to hispidulin and quercetin; Leu865,
Glu869, and Arg594 bonded to betaine and hispidulin;
and Asp356 bonded to quercetin and acarbose. Notably,
the amino acid residues that bonded to daidzein did not
bind to other ligands (Table 1).

Through in silico molecular docking studies, the models
of the interactions between the ligands and the alphaglucosidase protein were obtained. The interactions
between the protein and the ligands used in this study
help us understand the potential mechanisms of their
interactions. Compounds contained in R. tuberosa L.
aqueous root extracts, i.e., hispidulin and daidzein, have
the potential to be used as an inhibitor for alphaglucosidase protein, with the binding energies of −251.2
and −249.4 cal/mol, respectively. By contrast, betaine
has the least potential to be used as an inhibitor for the
enzyme, with the binding energy of −167.6 cal/mol. The
inhibition types of the ligands should be determined
further through in vitro enzyme kinetics studies.

Nonetheless, the 2D structure map of the alphaglucosidase ligands showed that all of the compounds
did not interact with the active sites or catalytic residues
of the alpha-glucosidase enzyme. This phenomenon was
observed for all ligands, even for acarbose, which is an
effective alpha-glucosidase enzyme inhibitor. This
finding is somewhat different from previous findings
that acarbose bonded to the active sites of human alphaglucosidase [35]. However, in [35], acarbose was
docked directly to the active sites of alpha-glucosidase
and bound to amino acid residues mostly through
hydrogen bonds [29] because acarbose is a competitive
inhibitor for the alpha-glucosidase enzyme [36]. Other
ligands, including quercetin, betaine, daidzein, and
hispidulin, are proposed to have a noncompetitive
inhibition model. Hence, these ligands did not bind to
the active site of the enzyme. To define the mode of
inhibition of the ligands, further studies of the enzyme
kinetics of alpha-glucosidase should be conducted.
The distinctive interaction affected the binding energy.
The important contributors to the structure and protein–
protein or ligand–receptor interaction are generally
hydrogen bonds. Moreover, the hydrogen bond is
critical to the assessment of the efficacy and specificity
of the protein target and proposed drug [37–39]. In this
study, the acarbose–alpha-glucosidase interaction had
the highest number of hydrogen bonds compared with
all other ligands. Hence, the acarbose–alpha-glucosidase
interaction had the lowest binding energy (i.e., −332.1
cal/mol).
Therefore, on the basis of the interaction types, energy
scores, and binding energies, acarbose is the most potent
antidiabetic drug through alpha-glucosidase inhibition,
followed by hispidulin, daidzein, and quercetin;
meanwhile, betaine has the lowest potential to be used
as an alpha-glucosidase inhibitor. Therefore, the order
of activity of the ligands based on the binding energy is
acarbose > hispidulin > daidzein > quercetin > betaine.
Makara J. Sci.
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